PBS Biotech Wins 2026 Cell Products Development of the Year Award
PBS Biotech, a developer of single-use bioreactor technologies for cell therapy manufacturing, has been named Cell Therapy Products Development of the Year 2026 by Life Sciences Review. The company was also recognized among the publication's Top Companies in Cell and Gene Therapy, highlighting its impact on advanced therapeutic manufacturing.
The recognition underscores PBS Biotech's commitment to helping cell therapy developers address the challenge of scaling manufacturing reliably while maintaining cell quality and function. Its patented Vertical-Wheel® bioreactor technology allows for gentle, low-shear cell culture, supporting the expansion and differentiation of sensitive cell types through all stages of development to commercial manufacturing.
Martin Simonetti, Chief Executive Officer of PBS Biotech, remarked on the significance of the award, stating, "As cell therapies continue to transform medicine, manufacturers need technologies that eliminate the traditional tradeoff between scalability and cell quality. We're honored that Life Sciences Review has recognized our team's dedication to advancing manufacturing solutions that help bring life-changing therapies to patients faster."
The Vertical-Wheel platform, unlike conventional stirred-tank bioreactors, is engineered for homogeneous mixing with low shear forces, which is beneficial for sensitive cell types such as induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), T cells, NK cells, CAR-T, CAR-NK, and pancreatic islet cells. The technology offers linear scalability, simplifying process development and accelerating technology transfer.
Life Sciences Review acknowledged PBS Biotech's customer-centric approach and commitment to innovation and collaborations in the cell and gene therapy landscape. The publication also highlighted the company's role in helping developers navigate critical manufacturing challenges as cell therapies move toward commercialization.
Looking ahead, PBS Biotech remains focused on broadening its technology portfolio to support customer success and enhance manufacturing solutions, aimed at accelerating the commercialization of transformative cell therapies.